Browse >
Home /
Vyvanse News / Press Release – New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Pro
Press Release – New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Pro
PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adhd Medication, Amphetamine, Cii, Firstcall, Lisdexamfetamine Dimesylate, Lse, Median Time, Medication, Nasdaq, Pharmacokinetic Profile, Plasma Concentration, Ppi, Prilosec, Prilosec Otc, Prnewswire, Proton Pump Inhibitor, Shire, Shp, Vyvanse
